Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Immune reconstitution with the use of bruton tyrosine kinase inhibitor treatment for patients with Waldenstrom's macroglobulinemia

View Full Paper
Ask AI
Bookmark
Share

Authors

TJTushar JainBHBenjamin Heyman

Discussion

Loading...

Member takes

Overview

Retrospective study demonstrates improved immune reconstitution and lower infection risk in Waldenstrom's macroglobulinemia patients treated with ibrutinib and rituximab.

Key Points

  • This research aims to evaluate the effects of Bruton tyrosine kinase inhibitors on immune reconstitution in Waldenstrom's macroglobulinemia.
  • Conducted a retrospective study involving 45 Waldenstrom's macroglobulinemia patients.
  • Analyzed treatment groups: CIT, BTKis, and rituximab.
  • Compared immune levels (IgM, IgA) and infection rates among treatment types.
  • 82.2% of patients achieved partial or very good partial responses with BTKi treatment.
  • Higher median IgA increase (33%) observed in BTKi group at 24 months compared to rituximab (9.6%) and CIT groups.
  • Only 50% of BTKi patients experienced infections, significantly lower than 71.4% in CIT and 68.4% in rituximab groups.

Cite This Study

Jain et al. (2025) studied this question.

synapsesocial.com/papers/693624dd4fa91c937236d1f3https://doi.org/10.1182/blood-2025-7105
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Btkis and DRC show a reduction of infections and need of hospitalization towards BR and other chemo-immunotherapies in waldenstrom macroglobulinemia.2025
  2. 2Efficacy and Safety of Bruton Tyrosine Kinase Inhibitors in Waldenström Macroglobulinemia: A Single-Center Retrospective Analysis2026
  3. 3The effects of bruton tyrosine kinase inhibitors on the waldenstrom macroglobulinemia microenvironment2025
  4. 4Clinical outcomes in newly diagnosed patients with Waldenström's macroglobulinaemia treated in a tertiary academic centre2026 · 1 citations
  5. 5High VGPR/CR rates with pirtobrutinib plus venetoclax in previously treated Waldenström macroglobulinemia: Results from a multicenter phase II study2025 · 5 citations